- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff Patton Reflects on OCM Performance Period 4 Results, Taking on 2-Sided Risk
Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.
Transcript
With OCM performance period 4 results now out, how did the results compare with the last 2 performance periods?
So, very similar. Every period we’ve generated savings against the target but every period we’ve not gotten a performance payment. The good news is as it applies to 2-sided risk, that means we would not have had any recruitment, so I think most likely we’re going to go and do 2-sided risk.
What are your thoughts on taking on 2-sided risk?
Risk is risk, so it makes everybody nervous, but with 4 consecutive performance periods where we’re in what we call the safe zone, we have a comfort level. We are investigating stop loss or reinsurance and I’ll have a lot more confidence if I have an insured downside.
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
October 20th 2025Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.
Read More
